URGN
$14.21
Revenue | $23.53Mn |
Net Profits | $-26.02Mn |
Net Profit Margins | -110.57% |
Urogen Pharma Ltd’s revenue jumped 30.06% since last year same period to $23.53Mn in the Q4 2023. On a quarterly growth basis, Urogen Pharma Ltd has generated 12.84% jump in its revenue since last 3-months.
Urogen Pharma Ltd’s net profit jumped 7.9% since last year same period to $-26.02Mn in the Q4 2023. On a quarterly growth basis, Urogen Pharma Ltd has generated -18.91% fall in its net profits since last 3-months.
Urogen Pharma Ltd’s net profit margin jumped 29.19% since last year same period to -110.57% in the Q4 2023. On a quarterly growth basis, Urogen Pharma Ltd has generated -5.38% fall in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -0.87 |
EPS Estimate Current Year | -0.87 |
Urogen Pharma Ltd’s earning per share (EPS) estimates for the current quarter stand at -0.87 - a -27.94% fall from last quarter’s estimates.
Urogen Pharma Ltd’s earning per share (EPS) estimates for the current year stand at -0.87.
Earning Per Share (EPS) | -0.72 |
Return on Assets (ROA) | -0.26 |
Return on Equity (ROE) | -14.81 |
Urogen Pharma Ltd’s earning per share (EPS) jumped 40.98% since last year same period to -0.72 in the Q4 2023. This indicates that the Urogen Pharma Ltd has generated 40.98% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Urogen Pharma Ltd’s return on assets (ROA) stands at -0.26.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Urogen Pharma Ltd’s return on equity (ROE) stands at -14.81.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2023-09-30 | -0.85 | -0.68 | 20% |
2023-05-11 | -1.33 | -1.3 | 2.26% |
2023-08-10 | -1.14 | -1.03 | 9.65% |
2024-03-14 | -0.68 | -0.72 | -5.88% |